Menu

Pipeline Overview*

PRODUCT1 Indication Pre-clinical Phase 1/2 Phase 3 Commercial
Talicia® H. pylori infection2
APPROVED BY U.S. FDA NOVEMBER 2019
MOVANTIK® Opioid induced constipation3
GLOBAL RIGHTS EXCLUDING EUROPE AND CANADA
Aemcolo® Travelers' Diarrhea4
U.S. EXCLUSIVE LICENSE
Donnatal® IBS and acute enterocolitis5
U.S. CO-PROMOTION
Mytesi® Non-infectious diarrhea in HIV/AIDS patients5
U.S. CO-PROMOTION
EnteraGam® Chronic diarrhea and loose stools7
U.S. EXCLUSIVE LICENSE
Esomeprazole Strontium DR Capsules GERD and other GI conditions6
U.S. COMMERCIALIZATION LICENSE
RHB-204 NTM infections
RHB-104 Crohn's disease
RHB-102
(Bekinda®)		 Gastroenteritis & gastritis
IBS-D
RHB-106 Bowel cleanser
Opaganib
(Yeliva®)		 Oncology indications and COVID-19
RHB-107
upamostat		 Oncology/GI and COVID-19
Other
 RIZAPORT®
(RHB-103)		 Migraine
* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies
1 Bekinda® (RHB-102) and Yeliva® (Opaganib) are proposed tradenames which are subject to FDA review and approval.
2 Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: here
3 Movantik® (naloxegol) is indicated for the treatment of opioid induced constipation (OIC) in adults with chronic non cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dosage escalation. For full prescribing information see: here
4 Aemcolo® (rifamycin) is indicated for the treatment of travelers diarrhea caused by noninvasive strains of Escherichia Coli  in adults. For full prescribing information see: here

Company Profile

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases.

Read more

Recent News

SEE ALL NEWS
Home | Site Map
Copyright © 2017-2020. RedHill Biopharma Ltd. All Rights Reserved. Created by Catom web design | SEO
Thank you for visiting RedHill's website at www.redhillbio.com ("RedHill Site"). By clicking "OK", you acknowledge and understand that you will be linked outside of the RedHill Site and into other independent third party websites ("Third Party Sites"). You further acknowledge and agree that we have no control over the Third Party Sites nor over any content contained therein. You further acknowledge that we are not responsible in any way for the availability, suitability, accuracy and completeness of any information or links contained in any of the Third Party Sites, nor do we endorse, or are we responsible or liable for, any services, content, advertisements, products or any materials on, or available from or through, any of the Third Party Sites. In addition, we urge you to carefully review each of the Third Party Sites' terms of service and privacy policies, if such exist, before visiting such Third Party Sites. Ok
Thank you for visiting RedHill's website at www.redhillbio.com ("RedHill Site"). By clicking "OK", you acknowledge and understand that you will be linked outside of the RedHill Site and into other independent third party websites ("Third Party Sites"). You further acknowledge and agree that we have no control over the Third Party Sites nor over any content contained therein. You further acknowledge that we are not responsible in any way for the availability, suitability, accuracy and completeness of any information or links contained in any of the Third Party Sites, nor do we endorse, or are we responsible or liable for, any services, content, advertisements, products or any materials on, or available from or through, any of the Third Party Sites. In addition, we urge you to carefully review each of the Third Party Sites' terms of service and privacy policies, if such exist, before visiting such Third Party Sites. Ok